The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•23 March 2026•

1 min read

Tarsus Pharmaceuticals Secures China Approval for TP-03, Triggers $15M Milestone Payment

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1China's National Medical Products Administration (NMPA) approved TP-03 (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis.

Tarsus Pharmaceuticals (NASDAQ: TARS) announced that China's National Medical Products Administration (NMPA) has approved TP-03 (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis. The drug is already marketed in the United States under the brand name XDEMVY. This regulatory milestone in China triggers a $15 million milestone payment to Tarsus, providing a significant boost to the company's non-dilutive capital. The expansion into the Chinese market represents a major strategic victory, broadening the global reach of the company's lead product. Investors view this development as a positive fundamental catalyst, combining immediate funding with long-term revenue growth potential. The approval underscores the drug's clinical efficacy and the company's ability to successfully navigate international regulatory landscapes.